Journal article
Differences in Safety of Nonsteroidal Antiinflammatory Drugs in Patients With Osteoarthritis and Patients With Rheumatoid Arthritis: A Randomized Clinical Trial
DH Solomon, ME Husni, KE Wolski, LM Wisniewski, JS Borer, DY Graham, P Libby, AM Lincoff, TF Lüscher, V Menon, ND Yeomans, Q Wang, W Bao, MF Berger, SE Nissen
Arthritis and Rheumatology | WILEY | Published : 2018
DOI: 10.1002/art.40400
Abstract
Objective: To determine the relative risks of cardiovascular (CV), gastrointestinal (GI), and renal adverse events during long-term treatment with celecoxib, compared with ibuprofen and naproxen, in patients with osteoarthritis (OA) and patients with rheumatoid arthritis (RA). Methods: A total of 24,081 patients with OA or RA who had a moderate or high risk for CV disease were enrolled internationally into a double-blind randomized controlled trial. Interventions included celecoxib at a dosage of 100–200 mg twice daily, ibuprofen at a dosage of 600–800 mg 3 times daily, or naproxen at a dosage of 375–500 mg twice daily. The main outcomes were the first occurrence of a major adverse CV event,..
View full abstractGrants
Funding Acknowledgements
The PRECISION trial and these analyses were funded by Pfizer. Dr. Solomon has received research support from Pfizer and royalties for a peer-reviewed chapter titled NSAIDS: Therapeutic use and variability of response in adults in UpToDate (2017). Dr. Husni has received consulting fees and/or honoraria from AbbVie, Bristol-Myers Squibb, Amgen, UCB, Regeneron, and Janssen (less than $10,000 each) and research support from Sanofi Genzyme. Dr. Borer has received consulting fees and/or honoraria from Pfizer (more than $10,000). Dr. Graham has received consulting fees from RedHill Biopharma, BioGaia, and Takeda (less than $10,000 each) research support from RedHill Biopharma. Dr. Libby has received research support from Novartis (less than $10,000). Dr. Lincoff has received consulting fees from Novo Nordisk (more than $10,000). Dr. Luscher has received consulting fees, speaking fees, and/or honoraria from Bayer Health Care (less than $10,000). Dr. Yeomans has received consulting fees and/or honoraria from Pfizer (less than $10,000). Drs. Bao and Berger own stock or stock options in Pfizer..